Published on 7 Oct 2024 on GuruFocus.com · via Yahoo Finance
Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating...
Total Revenue: $255 million for Q2 2024.NARCAN Sales: $120 million in Q2 2024.Anthrax MCM Sales: $39 million in Q2 2024.Smallpox MCM Sales: $18 million in Q2 2024.Other Product Sales: $7 million in Q2 2024.Bio Services Revenue: $65 million in Q2 2024.Adjusted EBITDA: Negative $10 million in Q2 2024.Total Segment Adjusted Gross Margin: 26% in Q2 2024.Cash and Total Liquidity: $70 million in cash and $83 million total liquidity as of June 30, 2024.Net Debt Position: $794 million as of June 30, 2024.Full Year 2024 Revenue Guidance: $1.05 billion to $1.125 billion.Commercial Product Sales Guidance: $450 million to $480 million for 2024.MCM Product Sales Guidance: $455 million to $490 million for 2024.Services Segment Revenue Guidance: $120 million to $130 million for 2024.Adjusted EBITDA Guidance: $140 million to $180 million for 2024.
Warning! GuruFocus has detected 6 Warning Signs with EBS.